Scientific Advisors

The scientific advisors of Apogenix are renowned experts with a proven scientific track record in the fields of apoptosis, CD95L and TRAIL mediated signal transduction pathways

Prof. Peter Krammer (Founder of Apogenix GmbH)
Prof. Krammer is one of the founders of Apogenix GmbH. He carried out ground-breaking research in the field of apoptosis, and his work has been key to understanding the pathways that control this mechanism of cell death. Prof. Krammer is author of more than 300 scientific publications on apoptosis research. He holds numerous awards and acknowledgements, including the Robert-Koch Prize; the German Cancer Prize; the Kitasato-Behring Prize; the Avery-Landsteiner Prize; the Jung Prize; and the 1st Class Order of Merit of the Federal Republic of Germany. Currently, Prof. Krammer is coordinator of the research programme 'Tumour Immunology' at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, where he leads the center's Division of Immunogenetics.

Prof. Henning Walczak (Founder of Apogenix GmbH)
Prof. Henning Walczak is also a founder of Apogenix GmbH. He completed his diploma and Ph.D. thesis between 1990 and 1995 in Prof. Krammer's department at the German Cancer Research Center (DKFZ). In January 1996 he joined Immunex Corporation in Seattle (USA). After his return to Germany in 1998, he took up a position as group leader in the department headed by Prof. Krammer at the German Cancer Research Center. In 1999 he was awarded the BioFuture Prize and was appointed head of the BioFuture research group "Apoptosis Regulation" at the DKFZ. In addition to his research activities, he served as CEO for Apogenix Biotechnology AG, the predecessor company of Apogenix GmbH, from 2000 until 2004. Since October 2007 he has been Professor at Imperial College in London, UK.

Prof. Ana Martin-Villalba 
Prof. Ana Martin-Villalba studied medicine at the University of Murcia in Spain and in Leeds (UK). She graduated in 1995 and received her M.D. from the University of Heidelberg in 1998, where she investigated the involvement of death ligands (CD95L, TNF and TRAIL) in apoptosis occurring in the mammalian brain after a stroke. Following clinical and research periods at the University Hospital in Heidelberg and at the German Cancer Research Center in Prof. Krammer's department, Dr. Martin-Villalba became Head of the Junior Group - Molecular Neurobiology - at the DKFZ in 2006. In the same year, Dr. Martin-Villalba was awarded the Paul Ehrlich- and Ludwig Darmstaedter-Nachwuchspreis and the Heinz-Maier-Leibnitz Prize at the German Research Foundation. In 2007, she received the Walther and Christine Richtzenhain Award for her research on the involvement of CD95-mediated programmed cell death in Central Nervous System (CNS) injury.